Brief: Schott Pharma H1 EBITDA Margin At 26.6%
13/05/2026 06:13
May 13 (Reuters) - SCHOTT PHARMA AG & CO KGAA 1SXP.DE: REVENUE H1 2026 STOOD AT EUR 488.1 MILLION, SLIGHTLY ABOVE THE PREVIOUS YEAR’S LEVEL ANNUAL FORECAST FOR THE 2026 FINANCIAL YEAR CONFIRMED H1 FREE CASH FLOW MORE THAN DOUBLED TO EUR 45.4 MILLION H1 EBITDA MARGIN OF 26.6% (H1 2025: 27.0%) H1 CAPEX OF €50.1 MILLION WAS ROUGHLY IN LINE WITH THE €51.0 MILLION RECORDED IN THE SAME PERIOD OF THE PREVIOUS YEAR Source text: ID:nFWN41Q030 Further company coverage: 1SXP.DE (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600))